Dr. Robert Gundel

President and CEO

Robert Gundel Dr. Gundel has extensive industry experience from executive management positions at a number of leading biopharmaceutical companies prior to joining Amorfix in January 2010. Previously, Dr. Gundel was the Chief Scientific Officer at Heat Biologics, the Vice President and Head of Research at Elusys Therapeutics Inc., the Chief Scientific Officer at Arius Research, Inc., the Vice President, Preclinical Research and Scientific Corporate Development at XOMA (US), LLC., and Vice President, Pharmacology and Preclinical Research at Chiron Corporation. Earlier, Dr. Gundel also worked at Bayer Corporation as Director of Pharmacology after beginning his career in pharmaceutical R&D at Boehringer Ingelheim Pharmaceuticals, Inc.

Dr. Gundel earned his M.B.A. from Saint Mary's College, and his Ph.D. in physiology from New York Medical College. He has participated in over 45 national and international scientific meetings as an invited speaker and/or session chairperson. He has published more than 130 abstracts, articles in peer reviewed journals and book chapters. He served on the editorial board of several journals and is a co-inventor on several issued U.S. patents.

Dr Gundel is also a member of Amorfix's Board of Directors.

Dr. Neil Cashman

Chief Scientific Officer and Co-founder

Dr. Neil Cashman, CSO Dr. Cashman is a physician and scientist focused on neurodegenerative diseases. His first academic posting was at Montreal Neurological Institute and Hospital of McGill University. From 1998 to 2005, he was the Diener Professor of Neurodegenerative Diseases at the University of Toronto. In 2005, Professor Cashman moved to the University of British Columbia, where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases, and serves as the Director of the UBC ALS Centre. He has procured over $50 million in research grant funding from the CIHR, CRC, NCE, NIH, and various corporations for his work involving protein misfolding and prion technologies. He was awarded the Jonas Salk Prize for biomedical research in 2000, and was elected a Fellow of the Canadian Academy of Health Sciences in 2008. He is recognized worldwide as one of the leading research scientists pioneering the emerging fields of prion biology and protein misfolding diseases.

Dr Cashman is also a member of Amorfix’s Board of Directors.

Warren Whitehead

Chief Financial Officer

Warren Whitehead Warren Whitehead is a Certified Management Accountant who has held several senior financial management positions with pharmaceutical and biotechnology firms. He is the former CFO of Arius Research Inc., an anti-cancer antibody company (acquired by Roche in 2008), and former CFO of Labopharm Inc. (2000 to 2006) where he led several rounds of financing, including a cross-border NASDAQ offering. Prior positions include CFO of Resolution Pharmaceuticals Inc. and finance and business development at Glaxo Canada (now GlaxoSmithKline). He is a member of the board of Lorus Therapeutic Inc. and Plantform Corporation.

Mr. Whitehead holds an MBA from the University of Windsor.

Lynda P.S. Covello, LL.B., LL.M.

International Lawyer and Business Consultant,
Vice-President, Strategic Alliances

Lynda P.S. Covello Lynda is a respected business leader, lawyer and senior executive who has successfully guided biotech and biopharma businesses for more than 20 years through key challenges along the continuum of commercialization of innovation, from IP management strategy development through strategic alliance and IP-transaction negotiations to major financing and IPO. She has a rich skill set in technology licensing and commercialization, product development, intellectual property exploitation and international business. A recognized expert in IP and technology licensing worldwide, Lynda excels at balancing commercial and legal risk, strategy and entrepreneurship to deliver practical and profitable solutions in the fast-moving, highly competitive world of international business. A multi-lingual strategist, team-builder, effective communicator, engaging speaker, expert negotiator and creative problem-solver with a background in game theory who has sat on both sides of the boardroom table, Lynda is C.E.O. of LPC Consulting International, providing international IP business strategy support, and a principal in the law firm Ross Mongeon Covello & Co., providing legal services for domestic and international IP transactions.